Peroxisome proliferator-activated receptors (PPARs) are a family of three (PPARα, -β/δ, and -γ) nuclear receptors. In particular, PPARα is involved in regulation of fatty acid metabolism, cell growth and inflammation. PPARα mediates the cardiac fasting response, increasing fatty acid metabolism, decreasing glucose utilisation, and is the target for the fibrate lipid-lowering class of drugs. However, little is known regarding the endogenous generation of PPAR ligands. CYP2J2 is a lipid metabolising cytochrome P450, which produces anti-inflammatory mediators, and is considered the major epoxygenase in the human heart.
Expression of CYP2J2 in vitro results in an activation of PPAR responses with a particular preference for PPARα. The CYP2J2 products 8,9- and 11-12-EET also activate PPARα. In vitro, PPARα activation by its selective ligand induces the PPARα target gene pyruvate dehydrogenase kinase (PDK)4 in cardiac tissue. In vivo, in cardiac-specific CYP2J2 transgenic mice, fasting selectively augments the expression of PDK4.
Citation: Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, Miller-Degraff L, et al. (2009) The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα In Vitro and In Vivo. PLoS ONE 4(10): e7421. https://doi.org/10.1371/journal.pone.0007421
Editor: Daniel Tomé, AgroParisTech, France
Received: June 15, 2009; Accepted: September 21, 2009; Published: October 12, 2009
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was partly funded by grants from the British Heart Foundation (FS/04/047; FS/04/075; BS/02/002; PG/08/070/25464), Diabetes UK, the William Harvey Research Foundation, the Wellcome Trust, the European Community FP6 funding (LSHM-CT-2004-0050333), and the Intramural Research Programs of the National Institutes of Health, NIEHS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Exogenous PPAR activators include a number of fatty acids as well as a variety of eicosanoid, HETEs, HODEs, prostaglandins, and leukotrienes. A number of lipid-metabolising pathways have therefore been suggested as sources of PPAR ligands, however none really fully satisfy the criteria required for them to be regarded as ubiquitous endogenous PPAR ligand generators , . The cyclooxygenase, and 5-, 12/15-lipoxygenase pathways are good examples: prostanoid synthase enzymes and lipoxygenase isoforms have a highly tissue-specific expression pattern that do not fully match those of the PPARs and the effects of prostanoid/lipoxygenase enzyme inhibitors or the phenotypes of the corresponding knockout animal do not match those of the PPARs . Phospholipases  or lipoprotein lipase  can produce PPARα ligands from circulating lipoproteins. However, it is unclear whether these enzymes produce PPAR ligands universally. A very attractive hypothesis is that cytochrome P450 enzymes (CYPs) could provide the link. Similar to related eicosanoids, 8,9-, 11,12-, and 14,15-EET and their CYP4A hydroxylase metabolites can bind and activate a PPARα reporter gene , and 8,9-, 11,12- and 14,15-EETs can functionally activate both PPARα  and PPARγ ,  in vitro. It is not known however, which CYPs act as potential sources of the EETs, or whether CYPs or EETs mediate any functional effects on PPARs in vivo.
There are more than 500 CYP genes primarily associated with the metabolism and detoxification of foreign chemicals. A number of CYPs also catalyze the metabolism of lipids by epoxygenases lipoxygenase-like, and ω- and ω-1-hydroxylase activities . The CYP2 gene family of epoxygenases has approximately 25 members. CYP2J2 is the only CYP2J family member expressed in man, and it is localised in the heart and vasculature, throughout the gastro-intestinal and respiratory tracts and in the kidney , , where it catalyses the conversion of arachidonic acid via the epoxygenase pathway to anti-inflammatory and vascular-protective EETs . Here we show CYP2J2 activates PPARα in vitro and in vivo.
CYP2J2 activates PPARs in vitro in an autocrine manner
Transient transfection of the CYP2J2 cDNA in HEK293 cells produced significant expression of CYP2J2 protein (Figure 1A). The combination of CYP2J2 with PPARα (Figure 1A), PPARδ or PPARγ (Figure 1B) induced a synergistic activation of PPAR reporter genes, with a marked preference in terms of absolute activity for PPARα activation (Figure 1A). pDR-1 was used as a reporter gene for PPARδ activation due to the reported lack of efficacy for pACO on PPARδ responses . A functional PPAR was required for this activation, as no significant reporter gene activation was seen in cells co-transfected with vector reporter gene lacking the PPRE (data not shown), or when cells were co-transfected with dominant-negative (DN)-PPARα [12; Figure 1A). Similarly, the activation of PPAR reporter gene by co-transfection of PPARα and CYP2J2 required active CYP2J2, as the epoxygenase inhibitor SKF525A caused a concentration-dependent inhibition of PPARα-CYP2J2 induced PPAR reporter gene activation (Figure 2). These endogenous products of CYP2J2 act in an intracellular manner, as only when cells are co-transfected so that PPARα and CYP2J2 are co-expressed together in the same cell is a significant synergistic activation of the PPAR reporter gene detected (data not shown).
Dominant-negative (DN-)PPARα co-transfected into cells with CYP2J2 and PPARα abolished the ability of CYP2J2 to activate PPARα (A). HEK293 cells were transfected with PPAR reporter genes (pACO.gLuc for PPARα and –γ, and pDR-1 for PPARδ), and pcDNA-CYP2J2, pCMX-PPARα, pCMX-PPARδ, or pCMX-PPARγ alone, or co-transfected with CYP2J2 and the individual PPAR (2J2+α, 2J2+δ, and 2J2+γ). All PPAR reporter gene activation studies are represented as fold luciferase from PPAR response element transfection alone (control), normalised to total protein at 20 h post-transfection. Total plasmid DNA for transfections was normalised using pcDNA3.1 throughout. Data represents n = 9−12 replications from 4 separate experiments. * denotes p<0.05 by one-sample t-test between control and transfected cells. Inset (A) is Western blot for CYP2J2 and RT-PCR for PPARα in cells with either mock transfected (−; pcDNA3.1) or cells transfected with pcDNA-CYP2J2 and pcDNA-mPPARα (+).
Cells were co-transfected with PPAR reporter gene, CYP2J2 and PPARα, and treated with the epoxygenase inhibitor SKF525A (0–30 µM). SKF525A caused a concentration-dependant inhibition of PPAR reporter gene activation. Data represents n = 9−12 replications from 4 separate experiments.
CYP2J2 activates PPARα and inhibits NFκB activation
PPARα activation inhibits the activation of the pro-inflammatory and survival transcription factor NFκB , . IL-1β (10 ng/ml) induced NFκB reporter gene activation in HEK293 cells transfected with control plasmid cDNA. In cells transfected with the combination of CYP2J2 and PPARα, IL-1β induced NFkB activation was completely abolished (Figure 3). Inhibiting CYP2J2 with SKF525A (10 µM) restored the ability of IL-1β to activate NFκB in PPARα and CYP2J2 transfected cells (Figure 3)
IL-1β (10 ng/ml; 20 h) induced NFκB reporter gene activation in HEK293 cells. Cells co-transfected with CYP2J2 and PPARα abolished IL-1β-induced NFκB activation. Co-incubation of cells with the epoxygenases inhibitor SKF525A (10 µM) had no effect on IL-1β induced NFκB activation, but reversed the ability of PPARα and CYP2J2 to inhibit IL-1β induced NFκB activation. HEK293 cells were transfected with NFκB reporter gene and pcDNA-CYP2J2 and pCMX-PPARα. Data is represented as fold luciferase from NFκB reporter transfection alone (control), normalised to total protein at 20 h post-transfection. Total plasmid DNA for transfections was normalised using pcDNA3.1 throughout. Data represents n = 6 replications from 3 separate experiments. * denotes p<0.05 by paired t-test between IL-1b and treatments.
EETs activate PPARα
8,9- and 11,12-EET at nM concentrations induced activation of PPAR in HEK293 cells in the presence, but not absence of transfected PPARα (Figure 4). The CYP products 14,15-EET, or 5,6-DiHETE, the stable metabolite of 5,6-EET (Figure 4) or the linoleic acid metabolite of CYP2J2 leukotoxin (Figure 5A) had no effect on PPARα reporter gene activation. Although, 14,15-EET had no effect in our hands, consistent with the previous report , the CYP4A hydroxylase 14,15-EET metabolite was a potent PPARα activator (Figure 5B). The activation of PPARα responses by 8,9-EET or 11,12-EET was completely reversed when cells were co-transfected with dominant negative DN-PPARα (Figure 4B).
HEK293 cells were transfected with PPAR reporter gene in the presence or absence of PPARα. 20 h post transfection cells were treated with CYP2J2 products (0–10 µM), for a further 20 h. * denotes p<0.05 by one-way ANOVA followed by Bonferroni's post test. (B) 8,9-EET and 11,12-EET activation of PPARα responses were inhibited by co-transfection with dominant-negative DN-PPARα. Cells were transfected with a PPAR reporter alone or with PPARα, in the presence or absence of DN-PPARα. Cells were treated with CYP2J2 products as indicated (all at 1 µM). Data represents n = 9−12 replications from 3–4 separate experiments. * denotes p<0.05 by one-sample t-test between control and transfected cells.
(A) PPAR reporter gene activation is not induced by the linoleic acid CYP2J2 metabolite leukotoxin in the presence or absence of PPARα, but is potently induced by (B) the CYP4A 14,15-EET metabolite 20,14,15-HEET in the presence of PPARα. HEK293 cells were transfected with PPAR reporter gene in the presence or absence of PPARα. 20 h post transfection cells were treated with CYP2J2 products (0–10 µM), for a further 20 h.
PPARα activation induces PDK4 in cardiac tissue in vitro
PDK4 is a tissue specific PPARα target gene that facilitates fatty acid oxidation by “sparing” pyruvate for oxaloacetate formation , . The highly selective PPARα ligand GW7647 induced PDK4 mRNA in mouse cardiac tissue in culture in vitro (Figure 6); an effect which was abolished by co-incubation with the selective PPARα antagonist GW6471 (Figure 6), or if tissue was used from PPARα knockout mice (data not shown).
Fresh mouse heart tissue in culture was incubated in the presence or absence of the selective PPARα agonist GW7647 (10 nM) or antagonist GW6471 (3 µM) for 24 h and PDK4, PPARα and β-actin expression determined by RT-PCR. *denotes p<0.05 by one-sample t-test between control and treatments. Data represents mean±SEM of n = 9 incubations from 3 separate experiments.
Cardiac-specific CYP2J2 transgenic mice have an elevated PPARα response during fasting
The fasting response is a model of PPARα activation in vivo as a decline in insulin levels and/or a rise in lipid fuel availability facilitates PPARα activation and the up-regulation of PDK4. Moreover, this marked up-regulation of PDK4 expression in response to fasting is absent in PPARα knockout mice . Therefore, PDK4 is a robust index of PPARα activation in vivo. Expression of the related proteins PDK1, PDK2 and E1a are not regulated by PPARα, and were used as controls.
Cardiomyocyte-specific CYP2J2 transgenic (Tr) mice have been generated and have a normal heart anatomy and contractile function . Fed CYP2J2 Tr mice had no altered expression of PDK1, -2, -4 or E1a expression in the heart, kidney, or liver compared to wild type controls (Figure 6; and data not shown). In fasted mice, PDK4 protein expression was selectively up-regulated in the heart (Figure 7A and B), kidney and liver (Figure 7C) of wild type mice. In response to fasting, wild type male mice had an approximate 2–3 fold higher induction of cardiac PDK4 expression than female mice (9.3±2.4 male compared to 3.7±0.9 female; relative fold induction; n = 4−6). The basal PDK4 levels between male and female mice were equivalent, so this gender difference in PPARα activity/PDK4 expression upon fasting is gender specific.
Female wild-type or cardiac-specific CYP2J2 Tr mice were allowed food and water ad libitum, or fasted for 24 h. Figure (A) shows representative western blots for 2 of the 6 animals tested for PDK4, PDK1 (antibody has cross reactivity with PDK4 indicated by changes in the lower band) and E1a in the hearts of wild type (WT) or cardiac-specific CYP2J2 Tr mice (2J2); specific bands are identified by the arrows. Figures show the relative protein expression of PDK4 in the heart (B), kidney, and liver (C as indicated) and PDK1 and E1a in the heart (as indicated) in wild type (WT) and cardiac-specific CYP2J2 Tr (2J2), fed and fasted female mice. Data represents relative densitometry of protein compared to wild type fed controls for n = 4−6 separate animals in each group. Only the PPARα target gene PDK4 was induced on fasting both in the heart and kidney. Upon fasting there was an approximate doubling of PDK4 in the hearts (b), but not the kidney (e), or liver (f) of female cardiac specific CYP2J2 transgenic mice. * denotes p<0.05 by unpaired t-test between the fasting response in wild-type and CYP2J2 transgenic mice.
Upon fasting, male wild type and CYP2J2 Tr mice, had a comparable induction of cardiac PDK4 protein (9.3±2.4 wild type; 7.4±1.3 CYP2J2 Tr; fold expression; n = 4). In contrast, female CYP2J2 Tr exhibited a much greater induction of cardiac PDK4 protein upon fasting compared to wild- type controls (Figure 7). PDK1, PDK2 and E1a protein expression were unchanged by 24 h of fasting in any tissue tested (Figure 6, and data not shown).
Up-regulation of PDK4 expression is linked to a decline in circulating insulin concentrations , , . Upon fasting, both plasma insulin and blood glucose levels fell to equivalent levels in wild type and CYP2J2 Tr mice (Table 1). Fibrate administration is associated with suppression of circulating triglyceride levels , however, neither triglyceride nor non-esterified fatty acid concentrations were affected in wild type or CYP2J2 Tr mice (Table 1). Since no systemic metabolic differences were observed, any changes in PPAR response we conclude are due to the local cardiac specific activity of CYP2J2 in the transgenic mouse.
Endogenous CYPs and the cardiac fasting response
The use of pharmacological CYP inhibitors in vivo is complicated due both to lack of specificity of inhibitors and the great heterogeneity in CYP enzymes between species. We did however examine the fasting response in CYP2J5 knockout mice , the only murine CYP2J family member where a knockout has been generated. There was however no difference in the circulating blood glucose levels, or the heart, liver or kidney PDK4, or heart E1a expression levels (Table S1) between knockout and wild type male or female mice either under fed or fasted conditions.
The nature of endogenous PPAR ligands are still far from clear, as is whether PPARs act as general lipid sensors or whether high affinity ligands exist in the body. Here we show CYP2J2 can act as an endogenous epoxygenase source of high affinity PPAR ligands. When co-transfected together in vitro, CYP2J2 induces PPAR, in particular PPARα, activity. In cardiac-specific-CYP2J2 Tr mice, fasting greatly elevates the PPARα target gene PDK4. These results do not exclude a role for CYP2J2 or other CYPs as regulators of PPARβ/δ or –γ. Indeed we found CYP2J2 can activate PPARδ and PPARγ, (albeit it to lower absolute levels then PPARα in our transfection system) and it is known that lipid CYP products (though not the CYP responsible) are endogenous PPARγ activators, induced by laminar shear of human endothelial cells in vitro , .
Unlike other proposed PPAR ligand-generating enzymes (e.g. 12/15-lipoxygenase; ), CYP2J2 did not require additional arachidonic/linoleic acid substrate(s), suggesting a high level of functional coupling between the epoxygenases and PPARs. We also show for the first time a functional in vivo response for a PPAR ligand generating system. Our results do not rule out the role of other enzymes, such as phospholipases  or lipoprotein lipases  implicated in PPARα ligand generation. These enzymes are likely to produce PPAR ligands in parallel to CYPs, and/or supply free fatty acid substrates for CYPs to utilise.
8,9-EET, and 11,12-EET, but not 14,15-EET activated PPARα. 11,12-EET in contrast to 14-15-EET is highly anti-inflammatory and vascular protective , . Therefore, we propose that PPARα is a likely anti-inflammatory target for 11,12-EET and CYP2J2. Indeed we found the combination of PPARα and CYP2J2 abolished IL-1β induced NFκB activation; a central pro-inflammatory transcription factor and PPARα target , .
Many EETs, including 14,15-EET, can also act as cellular hyperpolarising agents , , however, since 14,15-EET was inactive in our system, hyperpolarization mechanisms are highly unlikely to be involved. Our results are consistent with previous findings that EETs and some of their metabolites can directly bind and activate PPARα –. Although 14,15-EET did not activate PPARα in our hands, its CYP4A hydroxylase 14,15-EET metabolite 20,14,15-HEET, was the post potent EET product we tested. EETs can be rapidly metabolised by at least 10 different intracellular pathways, and it is estimated that when given exogenously <10% is available free within the cell . Our results therefore do indicate that alternative CYP2J2 products exist or further unknown EET metabolites , ,  are potential endogenous PPARα activators.
There is considerable species difference between CYPs in man and in the mouse. CYP2J2 is the human isoform, in the mouse the situation is far more complex with up to 8 putative homologues (CYP2J5 – CYP2J13; ). Since epoxygenases are ubiquitous and potentially have many roles, examining the role of endogenous epoxygenases especially in the mouse is extremely difficult. We therefore chose as our main model the established cardiac specific CYP2J2-Tr mouse. We did however test the recently described CYP2J5 knockout mouse , the only CYP2J knockout available. However, we did not detect a change in the fasting response or in PDK4 expression, suggesting a lack of involvement of CYP2J5 in PPARα ligand generation or the more likely compensation from other mouse CYP2J or CYP2C EET-producing epoxygenases that are present.
The selective augmentation of PDK4 in cardiac-specific CYP2J2-Tr mice occurred only in female mice. The fasting PPARα response was much stronger in males, and we believe maximally activated. Interestingly, our results are consistent with known gender differences in cardiac PPARα responses in the mouse. Pharmacological stress of the hearts of PPARα knockout mice with Etomoxir to prevent mitochondrial fatty acid import, results in cardiac lipid accumulation and a 100% mortality of male mice but only 25% mortality of female mice .
In conclusion, in vitro CYP2J2 activates PPARα without exogenous stimuli. In vivo CYP2J2 does not appear to be rate-limiting as PPARα target gene (PDK4) expression is only augmented in cardiac-specific CYP2J2 transgenic mouse upon fasting. Therefore, CYP2J2 in vivo is an enzyme apparently quiescent, but capable or responding to changes in lipid availability to generate endogenous PPARα agonists and thereby integrate transcriptional fasting events. CYP2J2 products activate PPARs, in particular PPARα in vitro and in vivo. As lipid-metabolising CYP enzymes have a widespread expression, utilise a variety of lipid substrates and produce a large family of oxidised biologically active lipid mediators, we suggest that lipid metabolising CYPs may represent an important source of PPAR ligands throughout the body.
PPARα is known as a controller of lipid metabolism and inflammation. Linking CYP2J2 and epoxygenases to PPARα has many potential clinical implications. Variants of CYP2J2 with lower activity are known in some populations to be linked to an increased risk of coronary artery disease , . Epoxygenases such as CYP2J2 in addition to metabolising arachidonic acid may also regulate xenobiotic drug metabolism. Understanding how epoxygenases are regulated, the mediators they produce, and where they work, will give us novel information on biomarkers for dyslipidaemia and inflammation, allow us to understand side-effects of drugs metabolised by epoxygenases, and help us to design novel PPARα ligands based on the structure of high affinity EETs and their metabolites.
Materials and Methods
HEK293 cells were from ATCC. pEGFPN-1 and pNFkB-luc were from Clontech. pGL-2 was from Promega (Southampton, UK). pCMXmPPARα, pACOg.Luc, and h6/29 hPPARα were gifts from Dr Ruth Roberts (AstraZeneca; Maccelsfield, U.K.), pCMX-mPPARδ was from Dr Ronald Evans (Salk Institute, La Jolla, USA), pDR-1 was from Dr Bert Vogelstein (Johns Hopkins University, Baltimore, USA), pCMX-mPPARγ was from Dr Christopher Glass (UCSD, San Diego, USA). Novafector was from VennNova (Pompano Beach, FL, USA). Rabbit polyclonal anti-CYP2J2  and PDK2  were raised as previously described. Anti-PDK4 antibodies were generously provided by Professor Bob Harris (Indianapolis, USA). CYP2J2 metabolites were from Cayman Chemical Company (Axxora, Nottingham, UK). SKF525A was from Biomol (Affiniti Research Products, Exeter, UK). Plasma insulin ELISA was from Mercodia (Uppsala, Sweden). Plasma glucose kits were from Roche Diagnostics (Lewes, East Sussex, UK). WAKO kits for plasma triacylglycerol were from Alpha Labs. (Eastleigh, Hants, UK). ECL reagents, hyperfilm were from Amersham Biosciences (Little Chalfont, Buckinghamshire, UK). Bradford reagents for protein estimation were purchased from BioRad Ltd. (Hemel Hempstead, Hertfordshire. UK). All other reagents were from Sigma (Poole, Dorset, UK).
Cell culture and transfections
HEK293 were maintained in DMEM containing, supplemented with Antibiotic/Antimycotic mix, and 10% FCS; 37°C; 5% CO2; 95% air. Cells were transfected with Novafector and Luciferase assays performed, essentially as previously described  but modified for a 96 well format . Luciferase activity was normalised to cell protein (BCA assay). Global cellular changes, cell morphology, and GFP expression were recorded on a Nikon TE2000 inverted florescent microscope, with a SPOT RT digital camera. In some experiments organ culture of mouse cardiac tissue was performed, essentially as previously described .
All animal studies were approved by the National Institute of Environmental Health Sciences Animal Care and Use Committee.
Cardiac-specific CYP2J2 transgenic mice (α−MHC promoter driven) and littermate wild type C57BL6/J controls  along with CYP2J5 knockout mice  have been described previously. Animals were allowed food and water ad libitum or fasted for 24 h. In some experiments mice were given SKF525A (30 mg/kg; i.p) or vehicle (sterile PBS) immediately prior to initiation of the 24 h fasting/non-fasting period.
Immunoblotting and assays
PDK1, -2, -4 and E1a and CYP2J2 protein levels were determined as previously described , , . For animal experiments each representative immunoblot presented are results from a single gel exposed for a uniform duration, and each lane represents a preparation from a different mouse. Plasma immunoreactive insulin concentrations were measured by ELISA, using rat insulin as a standard. Plasma glucose concentrations were determined by a glucose oxidase method. Plasma NEFA and TAG levels were determined spectrophotometrically using commercial kits.
Blood glucose and PDK4 expression in female fed and fasted wild type and CYP2J5 knockout (−/−) mice. Wild type and CYP2J5 −/− mice have similar basal levels of plasma glucose. Following 24 h of fasting, blood glucose dropped in both wild type and CYP2J2 mice to equivalent levels, while the PPARalpha target gene PDK4 was induced to similar levels in the heart, liver and kidney. The non-PPARalpha target genes E1a and PDK2 (data not shown), were unaffected by fasting. Similar results were found in male mice. This data represents the mean±s.e.m. for n = 4 animals per group. * denotes p<0.05 by paired t-test between fed and fasted levels.
(0.03 MB DOC)
Conceived and designed the experiments: MS DZ LMD JAB MH TW DBB. Performed the experiments: JW DZ GG SS LMD JAB DBB. Analyzed the data: JW MS GG SS MH TW DBB. Contributed reagents/materials/analysis tools: DZ DBB. Wrote the paper: JW MS MH DBB.
- 1. Bishop-Bailey D, Wray J (2003) Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat 71: 1–22.D. Bishop-BaileyJ. Wray2003Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation.Prostaglandins Other Lipid Mediat71122
- 2. Marx N, Duez H, Fruchart JC, Staels B (2004) Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94: 1168–1178.N. MarxH. DuezJC FruchartB. Staels2004Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.Circ Res9411681178
- 3. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, et al. (2000) Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett 471: 34–38.P. DeleriveC. FurmanE. TeissierJ. FruchartP. Duriez2000Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner.FEBS Lett4713438
- 4. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, et al. (2003) Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 100: 2730–2735.O. ZiouzenkovaS. PerreyL. AsatryanJ. HwangKL MacNaul2003Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.Proc Natl Acad Sci U S A10027302735
- 5. Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, et al. (2002) The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 277: 35105–35112.LA CowartS. WeiMH HsuEF JohnsonMU Krishna2002The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands.J Biol Chem2773510535112
- 6. Fang X, Hu S, Xu B, Snyder G, Harmon S, et al. (2006) 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator activated receptor-alpha. Am J Physiol Heart Circ Physiol 290: H55–63.X. FangS. HuB. XuG. SnyderS. Harmon200614,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator activated receptor-alpha.Am J Physiol Heart Circ Physiol290H5563
- 7. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, et al. (2005) The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102: 16747–16752.Y. LiuY. ZhangK. SchmelzerTS LeeX. Fang2005The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.Proc Natl Acad Sci U S A1021674716752
- 8. Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, et al. (2004) Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 110: 1128–1133.Y. LiuY. ZhuF. RannouTS LeeK. Formentin2004Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells.Circulation11011281133
- 9. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059–36062.DC Zeldin2001Epoxygenase pathways of arachidonic acid metabolism.J Biol Chem2763605936062
- 10. Spiecker M, Liao JK (2005) Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433: 413–420.M. SpieckerJK Liao2005Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids.Arch Biochem Biophys433413420
- 11. He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335–345.TC HeTA ChanB. VogelsteinKW Kinzler1999PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.Cell99335345
- 12. Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD (1998) Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 19: 43–48.RA RobertsNH JamesNJ WoodyattN. MacdonaldJD Tugwood1998Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha).Carcinogenesis194348
- 13. Sugden MC, Holness MJ (2003) Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 284: E855–862.MC SugdenMJ Holness2003Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs.Am J Physiol Endocrinol Metab284E855862
- 14. Wu P, Peters JM, Harris RA (2001) Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun 287: 391–396.P. WuJM PetersRA Harris2001Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha.Biochem Biophys Res Commun287391396
- 15. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, et al. (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95: 506–514.J. SeubertB. YangJA BradburyJ. GravesLM Degraff2004Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.Circ Res95506514
- 16. Barger PM, Kelly DP (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10: 238–245.PM BargerDP Kelly2000PPAR signaling in the control of cardiac energy metabolism.Trends Cardiovasc Med10238245
- 17. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, et al. (2008) Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J 22: 4096–108.K. AthirakulJA BradburyJP GravesLM DeGraffJ. Ma2008Increased blood pressure in mice lacking cytochrome P450 2J5.FASEB J224096108
- 18. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, et al. (1999) Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400: 378–382.JT HuangJS WelchM. RicoteCJ BinderTM Willson1999Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.Nature400378382
- 19. Node K, Huo Y, Ruan X, Yang B, Spiecker M, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276–1279.K. NodeY. HuoX. RuanB. YangM. Spiecker1999Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.Science28512761279
- 20. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, p.seudogenes and alternative-splice variants. Pharmacogenetics 14: 1–18.DR NelsonDC ZeldinSM HoffmanLJ MaltaisHM Wain2004Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, p.seudogenes and alternative-splice variants.Pharmacogenetics14118
- 21. Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, et al. (1998) A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest 102: 1083–1091.F. DjouadiCJ WeinheimerJE SaffitzC. PitchfordJ. Bastin1998A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.J Clin Invest10210831091
- 22. Spiecker M, Liao J (2006) Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. Trends Cardiovasc Med 16: 204–208.M. SpieckerJ. Liao2006Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease.Trends Cardiovasc Med16204208
- 23. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, et al. (2007) CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 17: 349–358.CR LeeKE NorthMS BrayDJ CouperG. Heiss2007CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.Pharmacogenet Genomics17349358
- 24. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460–3468.S. WuCR MoomawKB TomerJR FalckDC Zeldin1996Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart.J Biol Chem27134603468
- 25. Sugden MC, Bulmer K, Gibbons GF, Holness MJ (2001) Role of peroxisome proliferator-activated receptor-alpha in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding. Arch Biochem Biophys 395: 246–252.MC SugdenK. BulmerGF GibbonsMJ Holness2001Role of peroxisome proliferator-activated receptor-alpha in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding.Arch Biochem Biophys395246252
- 26. Bishop-Bailey D, Hla T (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12, 14-prostaglandin J2. J Biol Chem 274: 17042–17048.D. Bishop-BaileyT. Hla1999Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12, 14-prostaglandin J2.J Biol Chem2741704217048
- 27. Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, et al. (2006) The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 66: 10120–10126.KE SwalesM. KorbonitsR. CarpenterDT WalshTD Warner2006The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.Cancer Res661012010126
- 28. Price S, Evans TW, Mitchell JA. Nitric oxide supports atrial function in sepsis: relevance to side effects of inhibitors in shock. Eur J Pharmacol 449: 279–285.Price S, Evans TW, Mitchell JA. Nitric oxide supports atrial function in sepsis: relevance to side effects of inhibitors in shock.Eur J Pharmacol449279285